CGP64222
| Code | Size | Price |
|---|
| TAR-T26999-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CGP64222, a peptoid Tat/transactivation response element inhibitor, inhibits human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
CAS:
186380-62-1
Formula:
C58H107N25O9
Molecular Weight:
1298.66
Purity:
0.98
SMILES:
NCCCCCCNCC(=O)N(CCCN=C(N)N)CC(=O)N(CCCN=C(N)N)CC(=O)N(CC(=O)N(CCCN=C(N)N)CC(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)N1CCC[C@H]1C(N)=O)Cc1ccccc1
References
1. Fu J, Xia A, Dai Y, Qi X. Design-Based Peptidomimetic Ligand Discovery to Target HIV TAR RNA Using Comparative Analysis of Different Docking Methods. Curr HIV Res. 2016;14(6):476-483. PubMed PMID: 27450546.
2. Bai RJ, Liu XY. [Transactivation of HIV-1 transcription and inhibitors]. Yao Xue Xue Bao. 2006 Apr;41(4):289-95. Review. Chinese. PubMed PMID: 16856471.
3. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des. 2005;11(14):1805-43. Review. PubMed PMID: 15892677.
4. Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem. 2004;4(9):883-93. Review. PubMed PMID: 15134547.